Home Clinical Topics FDA approves Synribo for chronic myelogenous leukemia
Clinical TopicsDrugs and DevicesHealthcare & TechnologyNewsOncologyWeb Exclusives

FDA approves Synribo for chronic myelogenous leukemia

Author(s):

On Oct. 26, the U.S. Food and Drug Administration (FDA) approved Synribo (omacetaxine mepesuccinate) for the treatment of adults with chronic myelogenous leukemia. Synribo blocks certain proteins that promote the development of cancerous cells. Read more.

Previous articleStudy: Reporting medical errors may help reduce them in multi-site clinical practices
Next articleWhat a Great Week For Midlife Women And Menopausal Hormone Therapy – Keeps And Dops!

RELATED ARTICLES

News

Study: Over 1.5 million children have lost a parent to COVID-19

A study recently published in The Lancet estimates more than 1.5 million children worldwide have lost at least one parent, custodial grandparent, or grandparent who...
Read more
ANA on the Frontline

How to transcend stress and soar as an early career nurse

Nursing can be a stressful profession, especially for early career nurses, but the pandemic has magnified the challenges. The good news is that nurses...
Read more
Clinical Topics

Support nurses with job embeddedness

Use this model to promote nurse retention. Takeaways: The recent pandemic, and potential consequential post-traumatic stress disorder, might affect nurse retention significantly. Strategically planned job...
Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Early Release Articles

Powered by  HCM   www.HealthComMedia.com

© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder